Sickle Cell Disease patients and the use of disease-modifying treatments
New disease-modifying treatments (DMTs), namely, crizanlizumab, L-glutamine, and voxelotor, have recently been approved.
Stay updated with breaking news from Clinformatics Data Mart Database. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New disease-modifying treatments (DMTs), namely, crizanlizumab, L-glutamine, and voxelotor, have recently been approved.
Higher odds of receiving DAA treatment seen for younger age, being seen by a gastroenterologist or infectious disease physician, having cirrhosis.
The study in JAMA Network Open evaluates the effectiveness of simultaneously administering the Pfizer-BioNTech BNT162b2 BA.4/5 COVID-19 vaccine and seasonal influenza vaccines versus separate administration. Results suggest similar or slightly increased COVID-19 outcomes and lower influenza-related outcomes with coadministration, particularly in those aged 65 and above.
12-month adherence to GLP1-RA or SGLT2i therapies was highest among individuals with T2D and/or heart failure with a low prescription co-payment.
Female adolescents also saw increases in anxiety disorders, ADHD, and depression